1. CDK12 loss leads to replication stress and sensitivity to combinations of the ATR inhibitor camonsertib (RP-3500) with PARP inhibitors. (October 2022) Authors: Setton, J.; Gallo, D.; Glodzik, D.; Kaiser, B.; Braverman, S.; Ubhi, T.; Fournier, S.; Selenica, P.; Laterreur, N.; Roulston, A.; Brown, G.; Morris, S.; Reis-Filho, J.; Zimmermann, M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗